These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. Levin MJ; Gershon AA; Weinberg A; Song LY; Fentin T; Nowak B; J Infect Dis; 2006 Jul; 194(2):247-55. PubMed ID: 16779732 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of live varicella virus vaccine in children with human immunodeficiency virus type 1. Armenian SH; Han JY; Dunaway TM; Church JA Pediatr Infect Dis J; 2006 Apr; 25(4):368-70. PubMed ID: 16567993 [TBL] [Abstract][Full Text] [Related]
4. The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children. Taweesith W; Puthanakit T; Kowitdamrong E; Bunupuradah T; Wongngam W; Phasomsap C; Apornpong T; Bouko C; Pancharoen C Pediatr Infect Dis J; 2011 Apr; 30(4):320-4. PubMed ID: 20975615 [TBL] [Abstract][Full Text] [Related]
5. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ; Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343 [TBL] [Abstract][Full Text] [Related]
6. Varicella vaccination in HIV-1-infected children after immune reconstitution. Bekker V; Westerlaken GH; Scherpbier H; Alders S; Zaaijer H; van Baarle D; Kuijpers T AIDS; 2006 Nov; 20(18):2321-9. PubMed ID: 17117018 [TBL] [Abstract][Full Text] [Related]
7. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule. American Academy of Pediatrics Committee on Infectious Diseases Pediatrics; 2007 Jul; 120(1):221-31. PubMed ID: 17606582 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Vesikari T; Baer M; Willems P Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a two-dose regime of varicella vaccine in children with cancers. Leung TF; Li CK; Hung EC; Chan PK; Mo CW; Wong RP; Chik KW Eur J Haematol; 2004 May; 72(5):353-7. PubMed ID: 15059071 [TBL] [Abstract][Full Text] [Related]
10. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Kuter B; Matthews H; Shinefield H; Black S; Dennehy P; Watson B; Reisinger K; Kim LL; Lupinacci L; Hartzel J; Chan I; Pediatr Infect Dis J; 2004 Feb; 23(2):132-7. PubMed ID: 14872179 [TBL] [Abstract][Full Text] [Related]
11. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Lopez AS; Guris D; Zimmerman L; Gladden L; Moore T; Haselow DT; Loparev VN; Schmid DS; Jumaan AO; Snow SL Pediatrics; 2006 Jun; 117(6):e1070-7. PubMed ID: 16740809 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Goh P; Lim FS; Han HH; Willems P Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370 [TBL] [Abstract][Full Text] [Related]
13. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine. Shinefield HR; Black S; Kuter BJ J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM; Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age. Silber JL; Chan IS; Wang WW; Matthews H; Kuter BJ Pediatr Infect Dis J; 2007 Jul; 26(7):572-6. PubMed ID: 17596796 [TBL] [Abstract][Full Text] [Related]
18. Antibody response after varicella vaccination in children treated with budesonide inhalation suspension or non-steroidal conventional asthma therapy. Murphy K; Ververeli K; Harvey BM; Duke AL; Chapas-Crilly J; Uryniak T; Lyzell E; Mezzanotte W Int J Clin Pract; 2006 Dec; 60(12):1548-57. PubMed ID: 17109664 [TBL] [Abstract][Full Text] [Related]
19. Humoral and cell-mediated immune responses in children and adults after 1 and 2 doses of varicella vaccine. Watson B J Infect Dis; 2008 Mar; 197 Suppl 2():S143-6. PubMed ID: 18419388 [TBL] [Abstract][Full Text] [Related]
20. Determinants of vaccine immunity in the cohort of human immunodeficiency virus-infected children living in Switzerland. Myers C; Posfay-Barbe KM; Aebi C; Cheseaux JJ; Kind C; Rudin C; Nadal D; Siegrist CA; ; Pediatr Infect Dis J; 2009 Nov; 28(11):996-1001. PubMed ID: 19820427 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]